Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1

William J. Sandborn, Bruce E. Sands, Sharif Uddin, Rana M. Qasim Khan, Richa Sagar Mukherjee

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science